3don MSN
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
CEO Bourla sees "a lot of opportunities that probably outweigh the risks" with the Trump administration, like working together on cancer treatments ...
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Pfizer's CEO, Albert Bourla, Ph.D., has attempted to downplay the investor threat. At the J.P. Morgan Healthcare Conference ...
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
Few CEOs know the double-edged nature of dealing with US President Donald Trump as viscerally as Pfizer’s Albert Bourla. In his first term, Trump championed the $18 billion Operation Warp Speed ...
Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company ...
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.
The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results